Pf Magazine
Welcome to your go-to source for the newest updates, insights, events, job openings, and advancements in the pharmaceutical sector. Our platform provides you with the tools to stay informed on your schedule. Whether it's through print, online, or social media, we deliver the essential information you need to advance your career.
Outlet metrics
Global
#3382262
United Kingdom
#411101
Health/Biotechnology and Pharmaceuticals
#285
Articles
-
1 week ago |
pf-media.co.uk | Emma Cooper
Sapio Sciences, the science-aware™ lab informatics platform, has announced the promotion of Gordon McCall to Chief Operating Officer (COO). McCall has served as the company’s Chief Financial Officer (CFO) since 2022 and brings a proven track record of leadership, strategic execution, and operational acumen.
-
2 weeks ago |
pf-media.co.uk | Emma Cooper
The National Institute for Health and Care Excellence (NICE) has recommended a new treatment option for chronic kidney disease, for use in the NHS. Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary immunoglobulin A nephropathy (IgAN), also known as Berger’s disease.
-
2 weeks ago |
pf-media.co.uk | Hannah McGregor
Gilead Sciences, Inc. will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, 30 May-3 June, and the 2025 European Hematology Association (EHA) Annual Congress, 12-15 June.
-
2 weeks ago |
pf-media.co.uk | Hannah McGregor
Herantis Pharma Plc (“Herantis”), a company developing disease-modifying therapies for Parkinson’s disease, has announced the first patients have been dosed in the final cohort of its Phase 1b clinical trial evaluating the safety and tolerability of HER-096 in patients with Parkinson’s disease. Parkinson’s disease is a devastating neurological condition affecting around 10 million people worldwide, for which there is currently no cure.
-
2 weeks ago |
pf-media.co.uk | Hannah McGregor
NICE are consulting on draft guidance for cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (CLN2), a type of Batten disease. NICE draft guidance does not, at present, recommend the treatment’s use for future patients with this rare, life limiting disease due to its high price and the limited evidence of long-term effectiveness.
Contact details
Address
123 Example Street
City, Country 12345
Email Patterns
Contact Forms
Contact Form
Website
http://pf-media.co.ukTry JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →